Rivastigmine
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Rivastigmine?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Rivastigmine (sold under the trade name Exelon among others) is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease.[4] The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects,[5] which typically include nausea and vomiting.[6]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Exelon, Prometax, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602009 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, transdermal patch |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60 to 72% |
Protein binding | 40% |
Metabolism | Liver, via pseudocholinesterase |
Elimination half-life | 1.5 hours |
Excretion | 97% in urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.120.679 |
Chemical and physical data | |
Formula | C14H22N2O2 |
Molar mass | 250.342 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions.[6]
It was patented in 1985 and came into medical use in 1997.[7]